Extended Data Fig. 6: Systemic responses to LND-CDN and liposome-CDN administration.
From: STING agonist delivery by tumour-penetrating PEG-lipid nanodiscs primes robust anticancer immunity
a-e, Groups of C57Bl/6 mice (n = 5 animals/group) were treated once by i.v. injection with 5 nmol LND-CDN (red), 5 nmol liposome-CDN (blue), or saline control (black). Shown are serum concentrations of liver enzymes (a) alanine aminotransferase, (b) aspartate aminotransferase, and (c) blood urea nitrogen with the normal ranges indicated by dashed horizontal lines. d, Inflammatory cytokines and chemokines measured by cytokine bead array as a function of time. e, Liver and spleens were collected at 48 hr post dosing for histopathological imaging. Scale bars 100 µm. f, Groups of C57Bl/6 mice (n = 6 (Non-treated control) or 8 (LND-CDN) animals/group) were inoculated with 3 × 105 MC38 tumour cells s.c. in the flank on day 0, then treated on days 7, 14, and 21 with 5 nmol LND-CDN. Serum was collected on day 28 for ELISA analysis of anti-PEG IgG. Shown are raw ELISA absorbances as a function of serum dilution (bottom x-axis) and binding of serial dilutions of a monoclonal anti-PEG antibody standard (‘STD mouse anti-PEG IgG’. top x-axis). Data are shown as mean ± SEM and analysed by two-way ANOVA with Tukey post-test statistical analysis: ns, not significant; *, p < 0.05; **, p < 0.01; ****, p < 0.0001.
